Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

Abstract

Background To evaluate demographics, family history, and previous medication use at enrollment in a subset of psoriasis patients with self-reported psoriatic arthritis (PsA) enrolled in Psoriasis Longitudinal Assessment and Registry (PSOLAR). Methods PSOLAR is an international, prospective, longitudinal, disease-based registry that collects data in patients receiving, or are eligible to receive, systemic or biologic treatments for psoriasis. Baseline demographic, disease characteristics, medical history, and prior medication use at enrollment were evaluated in PSOLAR psoriasis patients self-reporting PsA ( n = 4315); a subset of which had their diagnosis of PsA established by a healthcare provider (HCP; n = 1719); patients with psoriasis only ( n = 7775); and the overall PSOLAR population ( n = 12,090). Results At enrollment, demographic characteristics were distinct between psoriasis patients self-reporting PsA and psoriasis only patients. Of the patients with psoriasis self-reporting PsA, 44.4% had cardiovascular disease (CVD), 26.3% had psychiatric illness, and 3.2% had inflammatory bowel disease (IBD), with each more prevalent than among patients with psoriasis only ( p < 0.001). Overall, 17.5% of psoriasis patients self-reporting PsA had a family history of PsA, 29.8% had used systemic steroids, 39.5% had used nonsteroidal anti-inflammatory drugs, and 83.5% had used biologics. Conclusions Demographics, family history, and previous medication use were generally comparable between “PsA established by a HCP” patients and psoriasis patients self-reporting PsA in the PSOLAR registry, but there were statistical differences compared with the psoriasis only group regarding the prevalence of certain comorbidities (CVD, psychiatric illness, and IBD). These analyses provide important data regarding characteristics of psoriasis patients with self-reported PsA in PSOLAR. Trial registration NCT00508547 . Electronic supplementary material The online version of this article (10.1186/s41927-018-0034-7) contains supplementary material, which is available to authorized users.

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics

“…It has been reported in several studies that TNF inhibitors are associated with an increased risk of SI in patients with psoriasis [2, 4–7] and in patients with PsA or RA [8, 21, 22]. Our results confirmed these findings among PSOLAR psoriasis patients self-reporting PsA [20]. These results are consistent with those previously reported for the overall PSOLAR population of patients with psoriasis, in which a higher risk of serious infections with the monoclonal TNF inhibitors compared with non-methotrexate and non-biologic therapies was found, with no increased risk observed with ustekinumab or etanercept [7].…”

“…A total of 12,090 patients with psoriasis were enrolled in the PSOLAR registry at the time of this analysis. Overall, approximately 36% ( n = 4315) of the psoriasis patients in PSOLAR self-reported having PsA [7, 20].…”

“…In the current report, all patients had psoriasis, including a subset of which self-reported a diagnosis of PsA ( N = 4315) [20]. Of the patients self-reporting PsA, a subset self-reported that their healthcare provider established a diagnosis of PsA ( N = 1719), but with no further confirmation by the investigator [20]. Patients were enrolled at international dermatology sites including academic centers, hospitals, and community practices [18].…”

Systematic Review and Meta-Analysis of Inflammatory Bowel Disease Adverse Events with Anti-Interleukin 17A Agents and Tumor Necrosis Factor Inhibitors in Rheumatic Disease and Skin Psoriasis

“…We reported a similar frequency of IBD events to previous cohorts, which have observed IBD event rates of 0.1-0.2 /100 PY in psoriasis, 0.16-0.57/100 PY in psoriatic arthritis, and 1-2/100 PY in spondyloarthritis patients on biologic therapy [19,[42][43][44][45]. Reporting bias may have increased the new IBD event count, as many RCTs consist of biologic-naive subjects who may not have previously been regularly asked about bowel symptoms.…”

Comorbidities in psoriatic arthritis: a systematic review and meta-analysis

“…The selected studies comprised of 10 from the USA, 7 from the UK, 6 from Spain, 4 from Italy, 3 from Canada, 2 each from Denmark, Turkey, and France, and 1 each from Belgium, Brazil, Russia, the Netherlands, Romania, Israel, Taiwan and Hong Kong. Two studies recruited participants from multiple countries [ 6 , 7 ].

Fig.

…”